Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...

Bearish flow noted in Merck (MRK) with 177,294 puts trading, or 7x expected. Most active are Feb-25 98 puts and Feb-25 100 puts, with total ...

Verizon's dividend yield and Merck’s growth lead the Dow Dogs. Read why they’re set for solid returns, with other top picks ...

Highlights,Citigroup revised its price target for Merck & Co., adjusting it from $125 to $115 while maintaining an optimistic ...

We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before ...

Highlights,Price target adjustment,Citigroup analysts revised Merck’s target from $125.00 to $115.00.,Stock performance trends,The company’s stock has fluctuated within a defined price range over the ...

Merck’s Gardasil sales fell short of expectations in the fourth quarter, and the company pulled its long-term target of $11 ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Robert F Kennedy Jr's nomination now will face a full senate vote, despite concerns about the work he's done to sow doubts ...

Merck swung to a fourth-quarter profit as sales grew and even exceeded Wall Street's estimates, boosted in part by the performance of top asset Keytruda. The drug company logged net income of $3.74 ...

Robert F. Kennedy Jr. also disclosed that he had reached at least one settlement agreement with a company or individual that ...

Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our Earnings Yield Investor model based on the published strategy ...